BioAtla Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 41

Employees

  • Stock Symbol
  • BCAB

Stock Symbol

  • Share Price
  • $1.55
  • (As of Friday Closing)

BioAtla General Information

Description

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Contact Information

Website
www.bioatla.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 11085 Torreyana Road
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 11085 Torreyana Road
  • San Diego, CA 92121
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioAtla Stock Performance

As of 20-Nov-2026, BioAtla’s stock price is $1.55. Its current market cap is $2.58M with 1.67M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.55 $1.29 $1.07 - $59.50 $2.58M 1.67M 39.7K -$16.56

BioAtla Financials Summary

As of 30-Sep-2026, BioAtla has a trailing 12-month revenue of $8.75M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 6,485 31,237 (20,961) 128,558
Revenue 8,750 2,000 11,000 0
EBITDA (23,572) (60,077) (72,220) (128,553)
Net Income (23,573) (59,607) (69,776) (123,462)
Total Assets 1,109 13,828 52,422 119,658
Total Debt 5,874 6,200 836 2,460
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BioAtla Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BioAtla‘s full profile, request access.

Request a free trial

BioAtla Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of
Drug Discovery
San Diego, CA
41 As of 2025

Iselin, NJ
 

Zurich, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioAtla Competitors (61)

One of BioAtla’s 61 competitors is Outlook Therapeutics, a Formerly VC-backed company based in Iselin, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Outlook Therapeutics Formerly VC-backed Iselin, NJ
Molecular Partners Formerly VC-backed Zurich, Switzerland
Zymeworks Formerly VC-backed Vancouver, Canada
Inhibrx Formerly VC-backed La Jolla, CA
AC Immune Formerly VC-backed Lausanne, Switzerland
You’re viewing 5 of 61 competitors. Get the full list »

BioAtla Patents

BioAtla Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026169912-A1 Conditionally active antigen binding polypeptides to a b7-h3 (cd276) antigen, compositions, and methods of use thereof Pending 06-Feb-2025
WO-2025198961-A1 Methods and pharmaceutical composition for the treatment of adenoid cystic carcinoma Pending 19-Mar-2024
AU-2024267583-A1 Protein therapeutics for treatment of senescent cells Pending 07-May-2023
EP-4709912-A1 Protein therapeutics for treatment of senescent cells Pending 07-May-2023
WO-2024232976-A1 Protein therapeutics for treatment of senescent cells Inactive 07-May-2023 C07K16/18
To view BioAtla’s complete patent history, request access »

BioAtla Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioAtla Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BioAtla‘s full profile, request access.

Request a free trial

BioAtla ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.78 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view BioAtla’s complete esg history, request access »

BioAtla FAQs

  • When was BioAtla founded?

    BioAtla was founded in 2007.

  • Where is BioAtla headquartered?

    BioAtla is headquartered in San Diego, CA.

  • What is the size of BioAtla?

    BioAtla has 41 total employees.

  • What industry is BioAtla in?

    BioAtla’s primary industry is Drug Discovery.

  • Is BioAtla a private or public company?

    BioAtla is a Public company.

  • What is BioAtla’s stock symbol?

    The ticker symbol for BioAtla is BCAB.

  • What is the current stock price of BioAtla?

    As of 20-Nov-2026 the stock price of BioAtla is $1.55.

  • What is the current market cap of BioAtla?

    The current market capitalization of BioAtla is $2.58M.

  • What is BioAtla’s current revenue?

    The trailing twelve month revenue for BioAtla is $8.75M.

  • Who are BioAtla’s competitors?

    Outlook Therapeutics, Molecular Partners, Zymeworks, Inhibrx, and AC Immune are some of the 61 competitors of BioAtla.

  • What is BioAtla’s annual earnings per share (EPS)?

    BioAtla’s EPS for 12 months was -$16.56.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process